Effect of benralizumab and mepolizumab on the AHR to QS
Both benralizumab and mepolizumab prevented the hyperresponsive myogenic
tone induced by QS in passively sensitized bronchi.
Benralizumab administered at concentrations ≥10 μg/ml significantly
reduced the AHR when compared with C+ bronchi (-499.43±9.98 mg/100mg
bronchial tissue, P<0.01 vs. C+), conversely at least 30 μg/ml
of mepolizumab were necessary to induce the same significant effect in
hyperresponsive airways (-381.54±45.90 mg/100mg bronchial tissue,
P<0.01 vs. C+) (Figure 6). Benralizumab at 10 μg/ml, but not
mepolizumab, inhibited the contractile response to QS at a level
significantly (P<0.05) lower than that detectable in C-
tissue.